Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Device-Generating Hydroxyl Radicals Kills Superbugs in Hospitals

By Labmedica staff writers
Posted on 30 Jan 2008
Air disinfection by hydroxyl radicals is being used to fight methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, Novovirus, and Escherichia Coli in hospitals.

It has long been known that these superbugs cannot survive outdoors because they are destroyed by the germ-killing properties of fresh-air. More...
However, in enclosed spaces such as hospital wards, surgeries, and offices, these microorganisms persist and, until now, there has been no safe or easy way to kill them.

Scientists proved that the naturally occurring element in fresh-air was also a key part of the human immune system. They identified the "Open Air Factor” as the hydroxyl radical (OH). Hydroxyl radicals are generated in a number of reactions essential to life. In the body, hydroxyl radicals are produced by cells to kill invading pathogens as an essential part of the body's natural defense systems. In the fresh air, hydroxyl radials are produced by the reaction of ozone and olefins, the natural scents of flowers and plants.

British scientists and engineers created a new device, the AD, which can generate hydroxyl radicals in enclosed places, in a way that is entirely safe to humans but which kills air-borne bacteria and viruses. AD is made of aerospace-grade aluminum alloys and exceeds all necessary safety requirements. Sunderland Royal (Sunderland, UK) is one of a number of National Health Service (NHS; UK) hospitals beginning to use AD as a central element in their fight against air-borne super bugs.

Tests conducted by the Health Protection Agency (HPA) and other independent experts prove that a heavily contaminated room is cleaned to below detectable levels of pathogens within a matter of minutes, and unlike standard cleaning of surfaces, the hydroxyl radicals continue to be just as effective in destroying superbugs when an infected person or material subsequently enters the room.

AD is a product of Inov8 Science (Buckingham, UK), a wholly-owed subsidiary of Mid-States Plc (Buckingham, UK), Mike Heath managing, director of Mid-States said, "We know that superbugs cannot survive in fresh-air, but clearly it is not practical to have the windows open all the time. The AD allows us to bring the outdoors indoors. We have developed a device that is economic, easy to use, and can operate continuously in rooms full of people. The AD is the product of over 40 years of British research and we believe it can be instrumental in the battle to beat hospital acquired infection.”

Initially, AD will be exclusively available to the UK healthcare industry.


Related Links:
Health Protection Agency
National Health Service
Inov8 Science Ltd

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.